Fractyl Health discontinues Rejuva GLP-1 gene therapy platform in pipeline reprioritization

Fractyl Health announced a steep reprioritization of its clinical pipeline, discontinuing development of Rejuva, its GLP-1 gene therapy platform and the first AAV-based gene therapy candidate to enter clinical development.

Detected & updated continuously · Source: Nebula